Adenosinekinase is the key metabolizing enzyme regulating cellular adenosine concentrations. Inhibition of adenosinekinase can selectively enhance the protective actions of adenosine during tissue trauma without producing the nonspecific effects associa
A-286501 is an orally active adenosinekinaseinhibitor (IC50=0.47 nM). A-286501 effectively attenuates nociception by a non-opioid, non-non-steroidal anti-inflammatory drug ADO, receptor mediated mechanism.
Adenosine 5'-phosphosulfate is an ATP and sulfate competitive inhibitor of ATP sulfurylase in humans, S. cerevisiae, and P. chrysogenum (Ki = 18, 2500, and 1500 nM, respectively). Adenosine 5'-phosphosulfate also inhibits human adenosine 5'-phosphosulfate kinase (Ki = 47.5 μM) to prevent sulfation.
AP23464 is a potent adenosine 5'-triphosphate (ATP)-based inhibitor of Src and Abl kinases, displays antiproliferative activity against a human CML cell line and Bcr-Abl-transduced Ba F3 cells (IC(50) = 14 nM. AP23464 ablates Bcr-Abl tyrosine phosphorylation, blocks cell cycle progression, and promotes apoptosis of Bcr-Abl-expressing cells. Biochemical assays with purified glutathione S transferase (GST)-Abl kinase domain confirmed that AP23464 directly inhibits Abl activity. Importantly, the low nanomolar cellular and biochemical inhibitory properties of AP23464 extend to frequently observed imatinib mesylate-resistant Bcr-Abl mutants, including nucleotide binding P-loop mutants Q252H, Y253F, E255K, C-terminal loop mutant M351T, and activation loop mutant H396P. AP23464 was ineffective against mutant T315I, an imatinib mesylate contact residue. The potency of AP23464 against imatinib mesylate-refractory Bcr-Abl and its distinct binding mode relative to imatinib mesylate warr......